

REFERENCES

Aakvaag A., Utaaker E., Thorsen T., Lea O.A. and Lahooti H. Growth control of human mammary cancer cells (MCF-7 cells) in culture: effect of estradiol and growth factors in serum-containing medium. *Cancer Res.* **50**: 7806-7810, 1990.

Ali S. and Coombs C.R. Endocrine-responsive breast cancer and strategies for combating resistance. *Nat. Rev. Cancer* **2**: 101-112, 2002.

Allred D.C., Clark G.M., Tandon A.K., Molina R., Tormey D.C., Osborne C.K., Gilchrist K.W., Mansour E.G., Abeloff M., Eudey L. and McGuire W.L. HER-2/*neu* in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of *in situ* carcinoma. *J.Clin. Oncol.* **10**: 599-605, 1992.

Allred D.C., Mohsin S.K. and Fuqua S.A.W. Histological and biological evolution of human premalignant breast disease. *Endocrine-Related Cancer* **8**: 47-61, 2001.

Alroy I. and Yarden Y. The ErbB signalling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. *FEBS Lett.* **410**: 83-86, 1997.

Al Saati T., Clamens S., Cohen-Knafo E., Faye J.C., Prats H., Coindre J.M., Wafflart J., Caverivière P., Bayard F. and Delsol G. Production of monoclonal antibodies to human estrogen receptor protein (ER) using recombinant ER (RER). *Int. J. Cancer* **55**: 651-654, 1993.

Anders C.K., Hsu D.S., Broadwater G., Acharya C.R., Foekens J.A., Zhang Y., Wang Y., Marcom P.K., Marks J.R., Febbo P.G., Nevins J.R., Potti A. and Blackwell K.L. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. *J. Clin. Oncol.* **26**: 3324-3330, 2008.

Anderson E. The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. *Breast Cancer Res.* **4**: 197-201, 2002.

Archev W.B., McEachern K.A., Robson M., Offit K., Vaziri S.A., Casey G., Borg A. and Arrick B.A. Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers. *Oncogene* **21**: 7034-7041, 2002.

Arnold A., Cossman J., Bakhshi A., Jaffe E.S., Waldmann T.A. and Korsmeyer S.J. Immunoglobulin gene rearrangements as unique clonal markers in human lymphoid neoplasms. *N. Engl. J. Med.* **309**: 1593-1599, 1983.

Bakas P., Liapis A., Vlahopoulos S., Giner M., Logotheti S., Creatsas G., Meligova A.K., Alexis M.N. and Zoumpourlis V. Estrogen receptor α and β in uterine fibroids: a basis for altered estrogen responsiveness. *Fertility and Sterility* **90**: 1878-1885, 2008.

Balakrishnan A., Yang J., Beattie C.W., Gupta T.K.D. and Nandi S. Estrogen receptor in dissociated and cultured human breast fibroadenoma epithelial cells. *Cancer Lett.* **34**: 233-242, 1987.

Balslev I., Christensen I.J., Rasmussen B.B., Larsen J.K., Lykkesfeldt A.E., Thorpe S.M., Rose C., Briand P. and Mouridsen H.T. Flow cytometric DNA ploidy defines patients with poor prognosis in node-negative breast cancer. *Int. J. Cancer* **56**: 16-25, 1994.

Barlogie B., Drewinko B., Schumann J., Gohde W., Dosik G., Latrelle J., Johnston D. and Freireich E. Cellular DNA content as a marker of neoplasia in man. *Am. J. Med.* **69**: 195-203, 1980.

Baselga J., Seidman A.D., Rosen P.P. and Norton L. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. *Oncology* **11**: 43-48, 1997.

Baselga J., Perez E.A., Pienkowski T. and Bell R. Adjuvant Trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. *The Oncologist* **11**: 4-12, 2006.

Beato M. Gene regulation by steroid hormones. *Cell* **56**: 335-344, 1989.

Beato M., Herrlich P. and Schutz G. Steroid hormone receptors: many actors in search of a plot. *Cell* **83**: 851-857, 1995.

Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. *Lancet* **2**: 104-107, 1896.

Beekman J.M., Allan G.F., Tsai S.Y., Tsai M-J and O'Malley B.W. Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. *Mol. Endocrinol.* **7**: 1266-1274, 1993.

Beerman H., Kluin P.M., Hermans J., van De Velde C.J.H. and Cornelisse C.J. Prognostic significance of DNA-ploidy in a series of 690 primary breast cancer patients. *Int. J. Cancer* **45**: 34-39, 1990.

Bertelli G., Garrone O., Merlano M., Occelli M., Bertolotti L., Castiglione F., Pepi F., Fusco O., Del Mastro L. and Leonard R.C. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. *Oncology* **69**: 471-477, 2005.

Berthois Y., Katzenellenbogen J.A. and Katzenellenbogen B.S. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen responsive cells in culture. *Proc. Natl. Acad. Sci. USA* **83**: 2496-2500, 1986.

Blenkiron C., Goldstein L.D., Thorne N.P., Spiteri I., Chin S.F., Dunning M.J., Barbosa Morais N.L., Teschendorff A.E., Green A.R., Ellis I.O., Tavaré S., Caldas C. and Miska E.A. MicroRNA expression profiling of human breast cancer

identifies new markers of tumor subtype. *Genome Biol.* **8**: R214, 2007.

Boccardo F., Rubagotti A., Puntoni M., Guglielmini P., Amoroso D., Fini A., Paladini G., Mesiti M., Romeo D., Rinaldini M., Scali S., Porpiglia M., Benedetto C., Restuccia N., Buzzi F., Franchi R., Massidda B., Distante V., Amadori D. and Sismondi P. Switching to anastrozole versus continued tamoxifen treatment for early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole Trial. *J. Clin. Oncol.* **23**: 5138-5147, 2005.

Bonnerterre J., Thürlimann B., Robertson J.F., Krzakowski M., Mauriac L., Koralewski P., Vergote I., Webster A., Steinberg M. and von Euler M. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. *J. Clin. Oncol.* **18**: 3748-3757, 2000.

Bowler J., Lilley T.J., Pittam J.D. and Wakeling A.E. Novel steroidal pure antiestrogens. *Steroids* **54**: 71-99, 1989.

Boyd M., Hildebrandt R.H. and Bartow S.A. Expression of the estrogen receptor gene in developing and adult human breast. *Breast Cancer Res. Treat.* **37**: 243-251, 1996.

Bronson F.H., Dagg C.P. and Snell G.D. Biology of the laboratory mouse. *Reproduction* **187**: 1975.

Bronzert D.A., Greene G.L. and Lippman M.E. Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018. *Endocrinology* **117**: 1409-1417, 1985.

Brooks S.C., Locke E.R. and Soule H.D. Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. *J. Biol. Chem.* **248**: 6251-6253, 1973.

Brueggemeier R.W., Hackett J.C. and Diaz-Cruz E.S. Aromatase Inhibitors in the Treatment of Breast Cancer. *Endocr. Rev.* **26**: 331-345, 2005.

Brunner N., Clarke R., Lippman M.E. and Dickson R.B. Models for studying the progression from hormone-dependent to hormone-independent growth in human breast cancer. In: *Growth Regulation of Cancer II*. Lippman M.E., Dickson R.B. (eds). Alan R. Liss: New York, 1990: pp 115.

Bryant W., Snowwhite A.E., Rice L.W and Shupnik M.A. The estrogen receptor (ER) α variant $\Delta 5$ exhibits dominant positive activity on ER-regulated promoters in endometrial carcinoma cells. *Endocrinology* **146**: 751-759, 2005.

Buzdar A.U., Marcus C., Holmes F., Hug V. and Hortobagyi G. Phase II evaluation of Ly156758 in metastatic breast cancer. *Oncology* **45**: 344-345, 1988.

Buzdar A. and Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. *Clin. Cancer Res.* **7** (9): 2620-2635, 2001.

Cairns J. Mutation, selection and the natural history of cancer. *Nature (Lond.)* **255**: 197-200, 1975.

Calin G.A., Sevignani C., Dumitru C.D., Hyslop T., Noch E., Yendamuri S., Shimizu M., Rattan S., Bullrich F., Negrini M. and Croce C.M. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. *Proc. Natl. Acad. Sci. USA* **101**: 2999-3004, 2004.

Calin G.A. and Croce C.M. MicroRNA signatures in human cancers. *Nat. Rev. Cancer* **6**: 857-866, 2006.

Cameron G. and Chambers R. Neoplasm Studies III. Organization of cells of human tumours in tissue culture. *Am. J. Cancer* **30**: 115-129, 1937.

Campbell-Thompson M., Lynch J. and Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ER β isoforms in colon cancer. *Cancer Research* **61**: 632-640, 2001.

Camplejohn R.S., Ash C.M., Gillett C.E., Raikundalia B., Barnes D.M., Gregory W.M., Richards M.A. and Millis R.R. The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single centre. *Br. J. Cancer* **71**: 140-145, 1995.

Carrel A. On the permanent life of tissues outside the organism. *J. Exp. Med.* **15**: 516-528, 1912.

Carruba G. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. *J. Cell Biochem.* **102**: 899-911, 2007.

Carter A.C. Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. *JAMA* **237**: 2079-2085, 1977.

Castles C.G., Fuqua S.A.W., Klotz D.M. and Hill S.M. Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. *Cancer Res.* **53**: 5934-5939, 1993.

Cepa M., Tavares da Silva E., Correia-da-Silva G., Roleira F. and Teixeira N.A. Structure-activity relationships of new A, D-ring modified steroids as aromatase inhibitors. Design, synthesis and biological activity evaluation. *J. Med. Chem.* **48**: 6379-6385, 2005.

Cepa M., Correia-da-Silva G., Tavares da Silva E.J., Roleira F.M.F., Borges M. and Teixeira N.A. New steroidal aromatase inhibitors: suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death. *BMC Cell Biol.* **9**: 41-54, 2008.

Chalbos D., Vignon F., Keydar I. and Rochefort H. Estrogens stimulate cell proliferation and induce secretory proteins in a human breast cancer cell line (T47D). *J. Clin. Endocrinol. Metab.* **55**: 276-283, 1982.

Chambraud B., Berry M., Redeuilh G. Chambon P. and Baulieu E.E. Several regions of human estrogen receptor are involved in the formation of receptor-heat shock protein 90 complexes. *J. Biol. Chem.* **33**: 20686-20691, 1990.

Chang E.C., Frasor J., Komm B. and Katzenellenbogen B.S. Impact of estrogen receptor β on gene networks regulated by estrogen receptor α in breast cancer cells. *Endocrinology* **147**: 4831-4842, 2006.

Chappell S.A., Johnson S.M., Shaw J.A. and Walker R.A. Expression of oestrogen receptor alpha variants in non-malignant breast and early invasive breast carcinomas. *J. Pathol.* **192**: 159-165, 2000.

Cheng A.M., Byrom M.W., Shelton J., Ford L.P. Antisense inhibition of human miRNAs and indicators for an involvement of miRNA in cell growth and apoptosis. *Nucleic Acids Res.* **33**: 1290-1297, 2005a.

Cheng G., Li Y., Omoto Y., Wang Y., Berg T., Nord M., Vihko P., Warner M., Piao Y-S. and Gustafsson J-A. Differential regulation of estrogen receptor (ER) {alpha} and ER {beta} in primate mammary gland. *J. Clin. Endocrinol. Metab.* **90**: 435-444, 2005b.

Chetrite G.S., Cortes-Prieto J., Philippe J.C., Wright F. and Pasqualini J.R. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissue. *J. Steroid Biochem. Mol. Biol.* **72**: 23-27, 2000.

Chung Y.L., Sheu M.L., Yang S.C., Lin C.H. and Yen S.H. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between HER-2/neu and cell membrane estrogen receptor in breast cancer. *Int. J. Cancer* **97**: 306-312, 2002.

Clark G.M., McGuire W.L., Hubay C.A., Pearson O.H. and Marshall J.S. Progesterone receptors as a prognostic factor in stage II breast cancer. *N. Engl. J. Med.* **309**: 1343-1347, 1983.

Clark G.M., Osborne C.K. and McGuire W.L. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. *J. Clin. Oncol.* **2**: 1102-1109, 1984.

Clark G.M. and McGuire W.L. Steroid receptors and other prognostic factors in primary breast cancer. *Semin. Oncol.* **15**: 20-25, 1988.

Clarke R., Dickson R.B. and Brunner N. The process of malignant progression in human breast cancer. *Ann. Oncol.* **1**: 401-407, 1990.

Clemens J.A., Bennett D.R., Black L.J. and Jones C.D. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. *Life Sci.* **32**: 2869-2875, 1983.

Cocconi G. First generation aromatase inhibitors – aminoglutethimide and testololactone. *Breast Cancer Res. Treat.* **30**: 57-80, 1994.

Cohen B.D., Siegall C.B., Bacus S., Foy L., Green J.M., Hellstrom I., Hellstrom K.E. and Fell H.P. Role of epidermal growth factor receptor family members in growth and differentiation of breast carcinoma. *Biochem. Soc. Symp.* **63**: 199-210, 1998.

Cole M.P., Jones C.T.A. and Todd I.D.H. A new anti-oestrogenic agent in late breast cancer. *Br. J. Cancer* **25**: 270-275, 1971.

Cooke T., George D., Shields R., Maynard P.V. and Griffiths K. Oestrogen receptors and prognosis in early breast cancer. *Lancet* **1**: 995-997, 1979.

Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., Jones S.E., Alvarez I., Bertelli G., Ortmann O., Coates A.S., Bajetta E., Dodwell D., Coleman R.E., Fallowfield L.J., Mickiewicz E., Andersen J., Lonning P.E., Cocconi G., Stewart A., Stuart N., Snowdon C.F., Carpentieri M., Massimini G. and Bliss J.M. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. *N. Engl. J. Med.* **350**: 1081-1092, 2004.

Cooper A.P. *The principles and practice of surgery*. vol.1 E. Cox, London: pp 333-335, 1836.

Coulson P.B., Thornthwaite J.T., Woolley T.W., Sugarbaker E.V. and Seckinger D. Prognostic indicators including DNA histogram type, receptor content, and staging related to human breast cancer patient survival. *Cancer Research* **44**: 4187-4196, 1984.

Cowley S.M., Hoare S., Mosselman S. and Parker M.G. Estrogen receptors α and β form heterodimers on DNA. *J. Biol. Chem.* **272**: 19858-19862, 1997.

Crandall D.L., Busler D.E., Novak T.J., Weber R.V. and Kral J.G. Identification of estrogen receptor β RNA in human breast and abdominal subcutaneous adipose tissue. *Biochem. Biophys. Res. Commun.* **248**: 523-526, 1998.

Critchley H.O., Henderson T.A., Kelly R.W., Scobie G.S., Evans L.R., Groome N.P. and Saunders P.T. Wild-type estrogen receptor (ER β 1) and the splice variant (ER β cx/ β 2) are both expressed within the human endometrium throughout the normal menstrual cycle. *J. Clin. Endocrinol. Metab.* **87**: 5265-5273, 2002.

Cui X., Schiff R., Arpino G., Osborne C.K. and Lee A.V. Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy. *J. Clin. Oncol.* **23** (30): 7721-7735, 2005.

Daffada A.A., Johnston S.R., Smith I.E., Detre S., King N. and Dowsett M. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. *Cancer Res.* **55**: 288-293, 1995.

De Sombre E.R., Carbone P.P., Jensen E.V., McGuire W.L., Wells S.A Jr., Wittliff J.L. and Lipsett M.B. Steroid receptors in breast cancer. *N. Engl. J. Med.* **301**: 1011-1012, 1979.

Desai A.J., Luqmani Y.A., Walters J.E., Coope R.C., Dagg B., Gomm J.J., Pace P.E., Rees C.N., Thirunavukkarasu V., Shousha S., Groome N.P., Coombes R. and Ali S. Presence of exon-5 deleted oestrogen receptor in human breast cancer: functional analysis and clinical significance. *Br. J. Cancer* **75**: 1173-1184, 1997.

De Vivo I., Hankinson S.E., Colditz G.A. and Hunter D.J. A functional polymorphism in the progesterone gene is associated with an increase in breast cancer risk. *Cancer Res.* **63**: 5236-5238, 2003.

Dobrzycka K.M., Townson S.M., Jiang S. and Oesterreich S. Estrogen receptor corepressors: A role in human breast cancer?
Endocr. Relat. Cancer **10**: 517-536, 2003.

Dodds E.C. and Lawson W. Synthetic oestrogenic agents without a phenanthrene nucleus. *Nature (Lond)* **137**: 56, 1936.

Don R.H., Cox P.T., Wainwright B.J., Baker K. and Mattick J.S. 'Touchdown' PCR to circumvent spurious priming during gene amplification. *Nucleic Acids Res.* **19**: 4008, 1991.

Dotzlaw H., Alkhalaf M. and Murphy L.C. Characterization of estrogen receptor variant mRNAs from human breast cancers. *Mol. Endocrinol.* **6**: 773-785, 1992.

Dotzlaw H., Leygue E., Watson P.H. and Murphy L.C. Expression of estrogen receptor-beta in human breast tumours. *J. Clin. Endocrinol. Metab.* **82**: 2371-2374, 1997.

Dotzlaw H., Leygue E., Watson P.H. and Murphy L.C. Estrogen receptor- β messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and regulation by progestins. *Cancer Res.* **59**: 529-532, 1999.

Dupont S., Krust A., Gansmuller A., Dierich A., Chambon P. and Mark M. Effect of single and compound knockouts of estrogen receptors alpha (ER α) and beta (ER β) on mouse reproductive phenotypes. *Development* **127**: 4277-4291, 2000.

Dupont W.D. and Page D.L. Risk factors for breast cancer in women with proliferative breast disease. *N. Engl. J. Med.* **31**: 146-151, 1985.

Duval D., Durant S. and Homo-Delarche F. Non-genomic effects of steroids. Interactions of steroid molecules with membrane structures and functions. *Biochim. Biophys. Acta* **737**: 409-442, 1983.

Earle W.R., Schilling E.L., Stark T.H., Straus N.P., Brown M.F. and Shelton E. Production of malignancy *in vitro* IV. The mouse fibroblast cultures and changes seen in the living cells. *J. Natl. Cancer Inst.* **4**: 165-212, 1943.

Elledge R.M., Green S., Pugh R., Allred D.C., Clark G.M., Hill J., Ravdin P., Martino S. and Osborne C.K. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group study. *Int. J. Cancer* **89** (2): 111-117, 2000.

Ellis L., Atadja P.W. and Johnstone R.W. Epigenetics in cancer: targeting chromatin modifications. *Mol. Cancer Ther.* **8**: 1409-1420, 2009.

Encarnacion C.A., Ciocca D.R., McGuire W.L., Clark G.M., Fuqua S.A.W. and Osborne C.K. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. *Breast Cancer Res. Treat.* **26**: 237-246, 1993.

Engel L.W. and Young N.A. Human breast carcinoma cells in continuous culture: a review. *Cancer Res.* **38**: 4327-4339, 1978.

Enmark E., Peltö-Huikko M., Grandien K., Lagercrantz S., Lagercrantz J., Fried G., Nordenskjöld M. and Gustafsson J-A. Human estrogen receptor β -gene structure, chromosomal localization, and expression pattern. *J. Clin. Endocrinol. Metab.* **82**: 4258-4265, 1997.

Erenburg I., Schachter B., Mira y Lopez R. and Ossowski L. Loss of an estrogen receptor isoform (ER $\alpha\Delta 3$) in breast cancer and the consequences of its reexpression: interference with estrogen-stimulated properties of malignant transformation. *Mol. Endocrinol.* **11**: 2004-2015, 1997.

Esber H., Payne I. and Bogden A. Variability of hormone concentrations and ratios in commercial sera used for tissue culture. *J. Natl. Cancer Inst.* **50**: 559-562, 1973.

Faber L.E., Sandmann M.L. and Stavely H.E. Progesterone binding proteins of the rat and rabbit uterus. *J. Biol. Chem.* **247**: 5648-5649, 1978.

Fan S., Wang J., Yuan R., Ma Y., Meng Q., Erdos M.R., Pestell R.G., Yuan F., Auborn K.J., Goldberg I.D. and Rosen E.M. BRCA1 inhibition of estrogen receptor signalling in transfected cells. *Science* **284**: 1354-1356, 1999.

Fasco M.J., Hurteau G.J. and Spivack S.D. Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. *Endocrinol.* **188**: 125-140, 2002.

Ferguson A.T. and Davidson N.E. Regulation of Estrogen Receptor α Function in Breast Cancer. *Crit. Rev. in Oncogenesis* **8**: 29-46, 1997.

Fernandez P., Wilson C., Hoivik D. and Safe S.H. Altered phenotypic characteristics of T47d human breast cancer cells after prolonged growth in estrogen-deficient medium. *Cell Biol. Int.* **22**: 623-633, 1998.

Fernö M., Baldetorp B., Borg Å., Olsson H., Sigurdsson H. and Killander D. Flow cytometric DNA index and S-phase fraction in breast cancer in relation to other prognostic variables and to clinical outcome. *Acta Oncol.* **31**: 157-165, 1992.

Fialkow P. Clonal origin of human tumours. *Annu. Rev. Med.* **30**: 135-143, 1979.

Filipowicz W., Bhattacharyya S.N. and Sonenberg N. Mechanisms of post transcriptional regulation by microRNAs: are the answers in sight? *Nat. Rev. Genet.* **9**: 102-114, 2008.

Fisher B., Gunduz N., Constantino J., Fisher E.R., Redmond C., Mamounas E.P and Siderits R. DNA flow cytometric analysis of primary operable breast cancer. *Cancer (Phila.)* **68**: 1465-1475, 1991.

Fisher B., Constantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L. and Wolmark N. Tamoxifen for prevention of breast cancer: report of

the National Surgical Adjuvant Breast and Bowel Project P-1 Study. *J. Natl. Cancer Inst.* **90**: 1371-1388, 1998.

Fisher B. From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century. *Eur. J. Cancer* **35**: 1963-1973, 1999.

Fitzpatrick S.L., La Chance M.P. and Schultz G.S. Characterization of epidermal growth factor receptor and action on human breast cancer cells in culture. *Cancer Res.* **44**: 3442-3447, 1984.

Focan C., Beauduin M., Majois F., Canon J.L., Cusumano G., Focan-Henrard D., and Lobelle J.P.: Adjuvant Breast Cancer Project, Belgium. High-dose oral medroxyprogesterone acetate or tamoxifen as adjuvant hormone therapy for node-negative early-stage breast cancer: randomized trial with 7-year update. *Clin. Breast Cancer* **5**: 136-141, 2004.

Foulds L. Neoplastic Development, Vol. 2. New York: Academic Press, 1975.

Fu X-D., Giretti M.S., Goglia L., Flamini M.I., Sanchez A.M., Baldacci C., Garibaldi S., Sitruk-Ware R., Genazzani A.R. and Simoncini T. Comparative actions of progesterone, medroxyprogesterone acetate, drospirenone and nesterone on breast cancer cell migration and invasion. *BMC Cancer* **8**: 166-178, 2008.

Fujimura T., Takahashi S., Urano T., Ogawa S., Ouchi Y., Kitamura T., Muramatsu M. and Inoue S. Differential expression of estrogen receptor beta (ERbeta) and its

C-terminal truncated splice variant ERbetax as prognostic predictors in human prostatic cancer. *Biochem. Biophys. Res. Commun.* **289**: 692-699, 2001.

Fuqua S.A., Fitzgerald S.D., Chamness G.C., Tandon A.K., McDonnell D.P., Nawaz Z., O'Malley B.W. and McGuire W.L. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. *Cancer Res.* **51**: 105-109, 1991.

Fuqua S.A., Fitzgerald S.D., Allred D.C., Elledge R.M., Nawaz Z., McDonnell D.P., O'Malley B.W., Greene G.L. and McGuire W.L. Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. *Cancer Res.* **52**: 483-486, 1992.

Fuqua S.A., Allred D.C. and Auchus R.J. Expression of estrogen receptor variants. *J. Cell Biochem. Suppl.* **17G**: 194-197, 1993.

Fuqua S., Wiltschke C., Castles C.G., Wolf D.C. and Allred D.C. A role for estrogen receptor variants in endocrine resistance. *Endocr. Rel. Cancer* **2**: 19-25, 1995.

Fuqua S.A.W., Wiltschke C., Zhang Q.X., Borg Å., Castles C.G., Friedrichs W.E., Hopp T., Hilsenbeck S., Mohsin S., O'Connell P. and Allred D.C. A hypersensitive estrogen receptor- α mutation in premalignant breast lesions. *Cancer Research* **60**: 4026-4029, 2000.

Fuqua S., Schiff R., Parra I., Moore J.T., Mohsin S., Osborne C.K., Clark G.M. and Allred D.C. Estrogen receptor β protein in human breast cancer: correlation with clinical tumor parameters. *Cancer Res.* **63**: 2434-2439, 2003.

Furberg A-S., Veierød M.B., Wilsgaard T., Bernstein L. and Thune I. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. *J. Natl. Cancer Instit.* **96**: 1152-1160, 2004.

Garcia Pedrero J.M., Zuazua P., Martinez-Campa C., Lazo P.S. and Ramos S. The naturally occurring variant of estrogen receptor (ER) ER Δ E7 suppresses estrogen-dependent transcriptional activation by both wild-type ER α and ER β . *Endocrinology* **144**: 2967-2976, 2003.

Garinis G.A., Patrinos G.P., Spanakis N.E. and Menounos P.G. DNA hypermethylation: when tumour suppressor genes go silent. *Hum. Genet.* **111**: 115-127, 2002.

Gaub M.P., Bellard M., Sheuer I., Chambon P. and Sassone-Corsi P. Activation of the ovalbumin gene by the estrogen receptor involves the *fos-jun* complex. *Cell* **63**: 1267-1276, 1990.

Gazic B., Pizem J., Bracko M., Cufer T., Borstnar S., Pohar-Marinsek Z. and Us-Krasovec M. S-phase fraction determined on fine needle aspirates is an independent prognostic factor in breast cancer – a multivariate study of 770 patients. *Cytopathology* **19**: 294-302, 2008.

German J. (ed.). Chromosome Mutation and Neoplasia. New York: Alan R. Liss, 1983.

Gey G.O., Coffman W.D. and Kubicek M.T. Tissue culture studies of the proliferative capacity of cervical carcinoma and normal epithelium. *Cancer Res.* **12**: 364-365, 1952.

Ghatge R.P., Jacobsen B.M., Schittone S.A. and Horwitz K.B. The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells. *Breast Cancer Res.* **7**: R1036-R1050, 2005.

Giacinti L., Claudio P.P., Lopez M. and Giordano A. Epigenetic information and estrogen receptor alpha expression in breast cancer. *Oncologist* **11**: 1-8, 2006.

Glauber J.G. and King D.T. The changing role of hormonal treatment in advanced breast cancer. *Semin. Oncol.* **19**: 308-316, 1992.

Glover J.F., Irwin J.T. and Darbre Philippa D. Interaction of phenol red with estrogenic and antiestrogenic action on growth of human breast cancer cells ZR-75-1 and T-47-D. *Cancer Res.* **48**: 3693-3697, 1988.

Gooch J.L. and Yee D. Strain-specific differences in formation of apoptotic DNA ladders in MCF-7 breast cancer cells. *Cancer Lett.* **144**: 31-37, 1999.

Graham M.L. II., Dalquist K.E. and Horwitz K.B. Simultaneous measurement of progesterone receptors and DNA indices by flow cytometry: analyses of breast cancer cell mixtures and genetic instability of the T47D line. *Cancer Res.* **49**: 3943-3949, 1989.

Graham M.L., Krett N.L., Miller L.A., Leslie K.K., Gordon D.F., Wood W.M., Wei L.L. and Horwitz K.B. T47D_{co} cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance. *Cancer Res.* **50**: 6208-6217, 1990.

Green S., Walter P., Kumar V., Krust A., Bornert J.M., Argos P. and Chambon P. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. *Nature (London)* **320**: 134-139, 1986.

Green S. and Chambon P. Oestradiol induction of a glucocorticoid-responsive gene by a chimaeric receptor. *Nature* **325**: 75-78, 1987.

Greene G.L., Nolan C., Engler J.P. and Jensen E.V. Monoclonal antibodies to the human estrogen receptor. *Proc. Natl. Acad. Sci. USA* **77**: 5115-5119, 1980.

Greene G.L. and Jensen E.V. Monoclonal antibodies as probes for estrogen receptor detection and characterization. *J. Steroid Biochem.* **16**: 353-359, 1982.

Greene G.L., Gilna P., Waterfield M., Baker A., Hort Y. and Shine J. Sequence and expression of human oestrogen receptor complementary DNA. *Science (Washington DC)* **231**: 1150-1154, 1986.

Gross G.E., Clark G.M., Chamness G.C. and McGuire W.L. Multiple progesterone receptor assays in human breast cancer. *Cancer Res.* **44**; 836-840, 1984.

Gullick W.J. and Srinivasan R. The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. *Breast Cancer Res. Treat.* **52**: 43-53, 1998.

Haddow A., Watkinson J.M. and Patterson E. Influence of synthetic oestrogens upon advanced malignant disease. *Br. Med. J.* **2**: 393-398, 1944.

Han F., Miksicek R., Clarke R. and Conrad S.E. Expression of an estrogen receptor variant lacking exon 3 in derivatives of MCF-7 cells with acquired estrogen independence or tamoxifen resistance. *J. Molec. Endocrinol.* **32**: 935-945, 2004.

Harrison R.G. Observations on the living developing nerve fiber. *Proc. Soc. Exp. Biol. Med.* **4**: 140-143, 1907.

Hemsell D.L., Grodin J., Brenner P.F., Siiteri P.K. and MacDonald P.C. Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma

androstenedione to estrone with age. *J. Clin. Endocrinol. Metab.* **38**: 476-479, 1974.

Henderson B.E., Ross R.K., Pike M.C. and Casagrande J.T. Endogenous hormones as a major factor in human cancer. *Cancer Research* **42**: 3232-3239, 1982.

Henderson B.E., Ross R. and Bernstein L. Estrogens as a cause of human cancer: the Richard and Hilda Rosenthal Foundation award lecture. *Cancer Res.* **48**: 246-253, 1988.

Henderson I.C. Endocrine therapy in metastatic breast cancer. In: *Breast Diseases*. Harris J.R., Hellman S., Henderson I.C and Kinne D.W (eds). J.B. Lippincott Co., Philadelphia: pp 398-428, 1987.

Henry J.A., Nicholson S., Farndon J.R., Westley B.R. and May F.E. Measurement of oestrogen mRNA levels in human breast tumours. *Br. J. Cancer* **58**: 600-605, 1988.

Herynk M.H. and Fuqua S.A. Estrogen receptor mutations in human disease. *Endocr. Rev.* **25**: 869-898, 2004.

Herynk M.H. and Fuqua S.A. Estrogen receptors in resistance to hormone therapy. *Adv. Exp. Med. Biol.* **608**: 130-143, 2007.

Holbro T., Civenni G. and Hynes N.E. The ErbB receptors and their role in cancer progression. *Exp Cell Res* **284**: 99-110, 2003.

Hopp T.A., Weiss H.L., Hilsenbeck S.G., Cui Y., Allred D.C., Horwitz K.B. and Fuqua S.A. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. *Clin. Cancer Res.* **10**: 2751-2760, 2004.

Horvath G., Leser G., Hahlin M. and Henriksson M. Exon deletions and variants of human estrogen receptor mRNA in endometrial hyperplasia and adenocarcinoma. *Int. J. Gynecol. Cancer* **10**: 128-136, 2000.

Horwitz K.B., McGuire W.L., Pearson O.H. and Segaloff A. Predicting a response to endocrine therapy in human breast cancer: a hypothesis. *Science* **189**: 726-727, 1975a.

Horwitz K.B., Costlow M.E. and McGuire W.L. MCF-7: a human breast cancer cell line with estrogen, androgen, progesterone and glucocorticoid receptors. *Steroids* **26**: 785-795, 1975b.

Horwitz K.B. and McGuire W.L. Estrogen control of progesterone receptor in human breast cancer. *J. Biol. Chem.* **253**: 2223-2228, 1978.

Horwitz K.B., Mockus M.B. and Lessey B.A. Variant T47D human breast cancer cells with high progesterone receptor levels despite estrogen and antiestrogen resistance. *Cell* **28**: 633-642, 1982.

Howell A., Barnes D.M., Harland R.N., Redford J., Bramwell V.H., Wilkinson M.J., Swindell R., Crowther D. and Sellwood R.A. Steroid-hormone receptors and survival after relapse in breast cancer. *Lancet* **17**: 588-591, 1984.

Huang Q., Gumireddy K., Schrier M., le Sage C., Nagel R., Nair S., Egan D.A., Li A., Huang G., Klein-Szanto A.J., Gimotty P.A., Katsaros D., Coukos G., Zhang L., Puré E. and Agami R. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. *Nat. Cell Biol.* **10**: 202-210, 2008.

Huggins C. and Hodges C.V. Studies on prostatic cancer. 1. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. *Cancer Res.* **1**: 293-297, 1941.

Hutcheson I.R., Knowlden J.M., Madden T-A., Barrow D., Gee J.M., Wakeling A.E. and Nicholson R.I. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. *Breast Cancer Res. Treat.* **81**: 81-93, 2003.

Huynh H.T. and Pollack M. Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. *Cancer Res.* **53**: 5585-5588, 1993.

Ingram D., Nottage E., Ng S., Sparrow L., Roberts A. and Willcox D. Obesity and breast cancer. *Cancer* **64**: 1049, 1989.

Inoue S., Ogawa S., Horie K., Hoshino S., Goto W., Hosoi T., Tsutsumi O., Muramatsu M. and Ouchi Y. An estrogen receptor β isoform that lacks exon 5 has dominant negative activity on both ER α and ER β . *Biochem. Biophys. Res. Commun.* **279**: 814-819, 2000.

Iorio M.V., Ferracin M., Liu C.G., Veronese A., Spizzo R., Sabbioni S., Magri E., Pedriali M., Fabbri M., Campiglio M., Menard S., Palazzo J.P., Rosenberg A., Musiani P., Volinia S., Nenci I., Calin G.A., Querzoli P., Negrini M. and Croce C.M. MicroRNA gene expression deregulation in human breast cancer. *Cancer Res.* **67**: 7065-7070, 2005.

Iwao K., Miyoshi Y., Egawa C., Ikeda N. and Nogushi S. Quantitative analysis of estrogen receptor- β mRNA and its variants in human breast cancers. *Int. J. Cancer* **88**: 733-736, 2000a.

Iwao K., Miyoshi Y., Egawa C., Ikeda N., Tsukamoto F. and Nogushi S. Quantitative analysis of estrogen receptor- α and - β messenger RNA expression in breast carcinoma by real-time polymerase chain reaction. *Cancer* **89**: 1732-1738, 2000b.

Jacquemier J.D., Hassoun J., Torrente M. and Martin P-M. Distribution of estrogen and progesterone receptors in healthy tissue adjacent to breast lesions at various stages – immunohistochemical study of 107 cases. *Breast Cancer Res. Treat.* **15**: 109-117, 1990.

Jarvinen T.A., Peltö-Huikko M., Holli K. and Isola J. Estrogen receptor β is coexpressed with ER α and PR and associated with nodal status, grade, and proliferation rate in breast cancer. *Am. J. Pathol.* **156**: 29-35, 2000.

Jolly D.J., Okayama H., Berg P., Esty A.C., Filpula D., Bohlen P., Johnson G.G., Shively J.E., Hunkapillar T. and Friedmann T. Isolation and characterization of a full-length expressible cDNA for human hypoxanthine phosphoribosyl-transferase. *Proc. Natl. Acad. Sci USA* **80**: 477-481, 1983.

Jones C., Payne J., Wells D., Delhanty J.D., Lakhani S.R. and Kortenkamp A. Comparative genomic hybridization reveals extensive variation among different MCF-7 cell stocks. *Cancer Genet. Cytogenet.* **117**: 153-158, 2000.

Jordan V.C. Selective estrogen receptor modulation: concept and consequences in cancer. *Cancer Cell* **5**: 207-213, 2004.

Jordan V.C. and Dowse L.J. Tamoxifen as an anti-tumour agent: effect on oestrogen binding. *J. Endocrinol.* **68**: 297-303, 1976.

Jordan V.C., Jacobson H.I. and Keenan E.J. Determination of estrogen receptor in breast cancer using monoclonal antibody technology: results of a multicenter study in the United States. *Cancer Res.* **46**: 4237s-4240s, 1986.

Kalhert S., Nuedling S., van Eickels M., Vetter H., Meyer R. and Grohe C. Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. *J. Biol. Chem.* **275**: 18447-18453, 2000.

Karnik P.S., Kulkarni S., Liu X-P., Budd G.T. and Bukowski R.M. Estrogen receptor mutations in tamoxifen-resistant breast cancer. *Cancer Res.* **54**: 349-353, 1994.

Kastner P., Krust A., Turcotte B., Stropp U., Tora L., Gronemeyer H. and Chambon P. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. *EMBO J.* **9**: 1603-1614, 1990.

Katzenellenbogen B.S., Montano M.M., Ekena K., Herman M.E. and McInerney E.M. William L. McGuire Memorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer. *Breast Cancer Res. Treat.* **44**: 23-38, 1997.

Keeling J.W., Ozer E., King G. and Walker F. Oestrogen receptor alpha in female fetal, infant, and child mammary tissue. *J. Pathol.* **191**: 449-451, 2000.

Keydar I., Chen L., Karbey S., Weiss F.R., Delarea J., Radu M., Chaitcik S. and Brenner H.J. Establishment and characterization of a cell line of human breast carcinoma origin. *Eur. J. Cancer* **15**: 659-670, 1979.

Khan S.A., Rogers M.A.M., Obando J.A. and Tamsen A. Estrogen receptor expression of benign breast epithelium and its association with breast cancer. *Cancer Res.* **54**: 993-997, 1994.

Kim S. H., Moores J.C., David D., Respass J.G., Jolly D.J. and Friedmann T. The organization of the human HPRT gene. *Nucleic Acids Res.* **14**: 3103-3118, 1986.

King W.L and Green G.L. Monoclonal antibodies localize estrogen receptor to the nuclei of target cells. *Nature* **307**: 293-304, 1984.

Klapper L.N., Kirschbaum M.H., Sela M. and Yarden Y. Biochemical and clinical implications of the ErbB/HER signalling network of growth factor receptors. *Adv. Cancer Res.* **77**: 25-79, 2000.

Klein G. Lymphoma development in mice and humans: diversity of initiation is followed by convergent cytogenetic evolution. *Proc. Natl. Acad. Sci. USA.* **76**: 2442-2446, 1979.

Klein-Hitpass L., Tsai S.Y., Greene G.L., Clark J.H., Tsai M-J. and O'Malley B.W. Specific binding of estrogen receptor to the estrogen response element. *Mol. Cell Biol.* **9**: 43-49, 1989.

Klotz D.M., Castles C.G., Fuqua S.A., Spriggs L.L. and Hill S.M. Differential expression of wild-type and variant ER mRNAs by stocks of MCF-7 breast cancer

cells may account for differences in estrogen responsiveness. *Biochem. Biophys. Res. Commun.* **210**: 609-615, 1995.

Knight W.A., Livingstone R.B., Gregory E.J. and McGuire W.L. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. *Cancer Res.* **37**: 4669-4671, 1977.

Koehorst S.G., Cox J.J., Donker G.H., Lopes da Silva S., Burbach J.P., Thijssen J.H. and Blankenstein M.A. Functional analysis of an alternatively spliced estrogen receptor lacking exon 4 isolated from MCF-7 breast cancer cells and meningioma tissue. *Mol. Cell Endocrinol.* **104**: 125, 1994.

Koenders P.G., Beex L.V., Kloppenborg P.W., Smals A.G. and Benraad T.J. Human breast cancer: Survival from first metastasis. Breast Cancer Study Group. *Breast Cancer Res. Treat.* **21**: 173-180, 1992.

Korenman S.G. Radioligand binding assay of specific estrogens using a soluble uterine macromolecule. *J. Clin. Endocrinol. Metab.* **28**: 127-130, 1968.

Kraus W.L., McInerney E.M. and Katzenellenbogen B.S. Ligand-dependent, transcriptionally productive association of the amino- and carboxy- terminal regions of a steroid hormone receptor. *Proc. Natl. Acad. Sci. USA* **92**: 2314-12318, 1995.

Kuiper G., Enmark E., Peltö-Huikko M., Nilsson S. and Gustafsson J.A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. *Proc. Natl. Acad. Sci. USA* **93**: 5920-5930, 1996.

Kuiper G.G.J.M., Carlsson B., Grandien K., Enmark E., Haggblad I., Nilsson S. and Gustafsson J-A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β . *Endocrinology* **138**: 863-870, 1997.

Kumar V., Green S., Stack G., Berry M., Jin J-R. and Chambon P. Functional domains of the human estrogen receptor. *Cell* **51**: 941-951, 1987.

Kushner P.J., Agard D.A., Greene G.L., Scanlan T.S., Shiau A.K., Uht R.M. and Webb P. Estrogen receptor pathways to AP-1. *J. Steroid Biochem. Mol. Biol.* **74**: 311-317, 2000.

Kute T.E., Muss H.B., Anderson D., Crumb K., Miller B., Burns D. and Dube L.A. Relationship of steroid receptor, cell kinetics, and clinical status in patients with breast cancer. *Cancer Res.* **41**: 3524-3529, 1981.

Lacroix M. and Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. *Breast Cancer Res. Treat.* **83**: 249-289, 2004.

Laidlaw I.J., Clarke R.B., Howell A., Owen O.W.M.C., Potten C.S. and Anderson E. The proliferation of normal human breast tissue, implanted into athymic nude

mice, is stimulated by oestrogen but not by progesterone. *Endocrinology* **136**: 164-171, 1995.

Lake D.E. and Hudis C. Aromatase Inhibitors in Breast Cancer: An Update. *Cancer Control* **9**: 490-498, 2002.

Lakshmanaswamy R., Guzman R.C., Yang J., Thordarson G., Talamantes F. and Nandi S. Prevention of mammary carcinogenesis by short-term estrogen and progestin treatments. *Breast Cancer Res.* **6**: R31-R37, 2004.

Lasfargues E.Y. and Ozzello L. Cultivation of human breast carcinomas. *J. Natl. Cancer Inst.* **21**: 1131-1147, 1958.

Lazennec G., Bresson D., Lucas A., Chauveau C. and Vignon F. ER β inhibits proliferation and invasion of breast cancer cells. *Endocrinology* **142**: 4120-4130, 2001.

Leav I., Lau K-M., Adams J.Y., McNeal J.E., Taplin M-E., Wang J., Singh H. and Ho S-M. Comparative studies of the estrogen receptors β and α and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. *Am.J.Pathol.* **159**: 79-92, 2001.

Levenson A.S. and Jordan V.C. Selective oestrogen receptor modulation: molecular pharmacology for the millennium. *Eur. J. Cancer* **35**: 1974-1985, 1999.

Levin E.R. Cellular functions of the plasma membrane estrogen receptor. *Trends Endocrinol. Metab.* **10**: 374-377, 1999.

Levin E.R. Cellular functions of plasma membrane estrogen receptors. *Steroids* **67**: 471-475, 2002.

Leygue E., Huang A., Murphy L.C. and Watson P.H. Prevalence of estrogen receptor variant messenger RNAs in human breast cancer. *Cancer Res.* **56**: 4324-4327, 1996a.

Leygue E.R., Watson P.H. and Murphy L.C. Estrogen receptor variants in normal human mammary tissue. *J. Natl. Cancer Inst.* **88**: 284-290, 1996b.

Leygue E., Dotzlaw H., Watson P.H. and Murphy L.C. Altered estrogen receptor α and β messenger RNA expression during human breast tumorigenesis. *Cancer Res.* **58**: 3197-3201, 1998.

Lindberg M.K., Moverare S., Skrtic S., Gao H., Dahlman-Wright K., Gustafsson J-Å. And Ohlsson C. Estrogen receptor (ER) $-\beta$ reduces ER α -regulated gene transcription, supporting a “Ying Yang” relationship between ER α and ER β in mice. *Mol. Endocrinol.* **17**: 203-208, 2003.

Lindgren P.R., Cajander S., Bäckström T., Gustafsson J-Å., Mäkelä S. and Olofsson J.I. Estrogen and progesterone receptors in ovarian epithelial tumors. *Mol. Cell. Endocrinol.* **221**: 97-104, 2004.

Ling V., Chambers A.F., Harris J.F and Hill R.P. Quantitative genetic analysis of tumour progression. *Cancer Metastasis Rev.* **4**: 173-194, 1985.

Lippman M.E. and Bolan G. Oestrogen-responsive human breast cancer in long-term tissue culture. *Nature (Lond)* **256**: 592-593, 1975.

Lippman M.E., Bolan G. and Huff K. The effects of estrogens and antiestrogens on hormone responsive human breast cancer cells in long-term tissue culture. *Cancer Res.* **36**: 4595-4601, 1976.

Lippman M.E., Dickson R.B., Gelman E.P., Rosen N., Knabbe C., Bates S., Bronzert D., Huff K. and Kasid A. Growth regulation of human breast cancer occurs through regulated growth factor secretion. *J. Cell Biochem.* **35**: 1-16, 1987.

Liu M.M., Albanese C., Anderson C.M., Hilty K., Webb P., Uht R.M., Price R.H. Jr., Pestell R.G. and Kushner P.J. Opposing action of estrogen receptors α and β on cyclin D1 gene expression. *J. Biol. Chem.* **277**: 24353-24360, 2002.

Lonning P.E. Aromatase inhibitors in breast cancer. Review. *Endocrin. Rel. Cancer* **11**: 179-189, 2004.

Lonning P.E., Bajetta E., Murray R., Tubiana-Hulin M., Eisenberg P.D., Mickiewicz E., Celio L., Pitt P., Mita M., Aaronson N.K., Fowst C., Arkhipov A., di Salle E., Polli A and Massimini G. Activity of exemestane in metastatic breast cancer after

failure of nonsteroidal aromatase inhibitors: a phase II trial. *J. Clin. Oncol.* **18**: 2234-2344, 2000.

Lowery A.J., Miller N., Devaney A., McNeill R.E., Davoren P.A., Lemetre C., Benes V., Schmidt S., Blake J., Ball G. and Kerin M.J. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/*neu* receptor status in breast cancer. *Breast Cancer Res.* **11**: R27, 2009.

Lu B., Leygue E., Dotzlaw H., Murphy L.J., Murphy L.C. and Watson P.H. Estrogen receptor- β mRNA variants in human and murine tissues. *Mol.Cell Endocrinol.* **138** : 199-203, 1998.

Mader S., Chambon P. and White J.H. Defining a minimal estrogen receptor DNA binding domain. *Nucleic Acids Res.* **21**: 1125-1132, 1993.

Madsen M.W., Reiter B.E., Larsen S.S., Briand P. and Lykkesfeldt A.E. Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells. *Cancer Res.* **57**: 585-589, 1997.

Mann S., Laucirica R., Carlson N., Younes P.S., Ali N., Younes A., Li Y. and Younes M. Estrogen receptor β expression in invasive breast cancer. *Hum. Pathol.* **32**: 113-118, 2001.

Markopoulos C., Berger U., Wilson P., Gazet J.C. and Coombes R.C. Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle. *Br. Med. J. (Clin. Res. Ed.)* **296**: 1349-1351, 1988.

Mattie M.D., Benz C.C., Bowers J., Sensinger K., Wong L., Scott G.K., Fedele V., Ginzinger D., Getts R. and Haqq C. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. *Mol. Cancer* **5**: 24, 2006.

Maynard P.V., Blamey R.W., Elston C.W., Haybittle J.L. and Griffiths K. Oestrogen receptor assay in primary breast cancer and early recurrence of the disease. *Cancer Res.* **38**: 4292-4295, 1978.

McCormack O., Harrison M., Kerin M.J. and McCann A. Role of the progesterone receptor (PR) and the PR isoforms in breast cancer. *Crit. Rev. Oncog.* **13**: 283-302, 2007.

McDonnell D.P., Connor C.E., Wijayaratne A., Chang C.Y. and Norris J.D. Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators. *Recent Prog. Horm. Res.* **57**: 295-316, 2002.

McEwen B.S., Alves S.E., Bulloch K. and Weiland N.G. Ovarian steroids and the brain: implications for cognition and aging. *Neurology* **48**: S8-S15, 1997.

McGuire W.L. Steroid hormone receptors in breast cancer treatment strategy. *Recent Prog. Horm. Res.* **36**: 135-156, 1980.

McGuire W.L., Carbone P.P., Sears M.E. and Escher G.C. Estrogen receptors in human breast cancer: an overview. In: *Estrogen Receptors in Human Breast Cancer*. McGuire W.L., Carbone P.P. and Vollmer E.P. (eds). Raven Press, New York: pp 1, 1975.

McGuire W.L., Horwitz K.B., Pearson O.H. and Segaloff A. Current status of estrogen and progesterone receptors in breast cancer. *Cancer* **39**: 2934-2947, 1977.

McGuire W.L., Chamness G.C. and Fuqua S.A. Estrogen receptor variants in clinical breast cancer. *Mol. Endocrinol.* **5**: 1571-1577, 1991.

McPherson S.J., Ellem S.J. and Risbridger G.P. Estrogen-regulated development and differentiation of the prostate. *Differentiation* **76**: 660-670, 2008.

Merkel D.E., Winchester D.J., Goldschmidt R.A., August C.Z., Wruck D.M. and Rademaker A.W. DNA flow cytometry and pathologic grading as prognostic guides in axillary lymph node-negative breast cancer. *Cancer (Phila.)* **72**: 1926-1932, 1993.

Miller W.R. Antiaromatase agents: preclinical data and neoadjuvant therapy. *Clin. Breast Cancer* **1**: S9-S14, 2000.

Miller W.R. and O'Neil J.S. The relevance of local oestrogen metabolism within the breast. *Proc. R. Soc. Edinburgh* **95B**: 203-217, 1989.

Miller W.R., Mullen P., Sourdain P., Watson C., Dixon J.M. and Telford J. Regulation of aromatase activity within the breast. *J. Steroid Biochem. Mol. Biol.* **61**: 193-202, 1997.

Miyoshi Y., Ando A., Shiba E., Taguchi T., Tamaki Y. and Noguchi S. Involvement of up-regulation of 17 β -hydroxysteroid dehydrogenase type I in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. *Int. J. Cancer* **94**: 685-689, 2001.

Montano M.M., Müller V., Trobaugh A. and Katzenellenbogen B.S. The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. *Mol. Endocrinol.* **9**: 814-825, 1995.

Morris C. and Wakeling A. Fulvestrant ('Faslodex') – a new treatment option for patients progressing on prior endocrine therapy. *Endocrine Rel. Cancer* **9**: 267-276, 2002.

Mosselman S., Polman J. and Dijkema R. ER-beta: identification and characterization of a novel human estrogen receptor. *FEBS Lett.* **392**: 49-53, 1996.

Mote P.A., Bartow S., Tran N. and Clarke C.L. Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. *Breast Cancer Res. Treat.* **72**: 163-172, 2002.

Mouridsen H., Gershanovich M., Sun Y., Perez-Carrion R., Boni C., Monnier A., Apffelstaedt J., Smith R., Sleeboom H.P., Janicke F., Pluzanska A., Dank M., Becquart D., Bapsy P.P., Salminen E., Snyder R., Lassus M., Verbeek J.A., Staffler B., Chaudri-Ross H.A. and Dugan M. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. *J. Clin. Oncol.* **19**: 2596-2606, 2001.

Muddawa L. and Liyanage T. Immunohistochemical assessment of hormone receptor status of breast carcinoma: interobserver variation of the quick score. *Indian J. Med. Sci.* **63**: 21-27, 2009.

Murphy L.C., Wang M., Coutt A. and Dotzlaw H. Novel mutations in the estrogen receptor messenger RNA in human breast cancers. *J. Clin. Endocrinol. Metab.* **81**: 1420-1427, 1996.

Murphy L.C., Dotzlaw H., Leygue E., Coutts A. and Watson P. The pathophysiological role of estrogen receptor variants in human breast cancer. *J. Steroid Biochem. Molec. Biol.* **65**: 175-180, 1998.

Murr S.M., Bradford G.E. and Geschwind I.I. Plasma leutinizing hormone, follicle stimulating hormone and prolactin during pregnancy in the mouse. *Endocrinology* **94**: 112-116, 1974.

Nabholtz J-M. Long-term safety of aromatase inhibitors in the treatment of breast cancer. *Ther. Clin. Risk Manag.* **4**: 189-204, 2008.

Nabholtz J.M., Buzdar A., Pollack M., Harwin W., Burton G., Mangalik A., Steinberg M., Webster A. and von Euler M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. *J. Clin. Oncol.* **18**: 3758-3767, 2000.

Narbaitz K., Stumpf W.E. and Sar M. Estrogen receptors in mammary gland primordia of fetal mouse. *Anat. Embryol.* **158**: 161-166, 1980.

Nathanson I.T. Clinical investigative experience with steroid hormones in breast cancer. *Cancer* **5**: 754-762, 1952.

Nawata H., Bronzert D. and Lippman M.E. Isolation and characterization of a tamoxifen resistant cell line derived from MCF-7 human breast cancer cells. *J. Biol. Chem.* **256**: 5016-5021, 1981.

Nemere I., Pietras R.J and Blackmore P.F. Membrane receptors for steroid hormones: Signal transduction and physiological significance. *J. Cell Biochem.* **88**: 438-445, 2003.

Netto G.J., Cheek J.H., Zachariah N.Y., Romer J.C., Lee C.F., Schoenfeld R. and Chakmakjian Z.H. Steroid receptors in benign mastectomy tissue. *Am. J. Clin. Path.* **94**: 14-17, 1990.

Nicolson G. and Milas L. Cancer Invasion and Metastasis: Biologic and Therapeutic Aspects (eds.). New York: Raven Press, 1984.

Norris J.D., Fan D., Kerner S. A. and McDonnell D.P. Identification of a third autonomous activation domain within the human estrogen receptor. *Mol. Endocrinol.* **11**: 747-754, 1997.

Nowell P. The clonal evolution of tumor cell populations. *Science (Wash. DC)* **194**: 23-28, 1976.

Nowell P. Cytogenetics. In: F.Becker (ed.) Cancer: A Comprehensive Treatise, Ed. 2, Vol 1, pp. 3-46. New York: Plenum Publishing Corp., 1982.

Nowell P.C. Mechanisms of tumor progression. *Cancer Res.* **46**: 2203-2207, 1986.

Nugoli M., Chuchana P., Vendrell J., Orsetti B., Ursule L., Nguyen C., Birnbaum D., Douzery E.J., Cohen P. and Theillet C. Genetic variability in MCF-7 sublines:

evidence of rapid genomic and RNA expression profile modifications. *BMC Cancer* **3**: 13, 2003.

Ogawa S., Inoue S., Watanabe T., Hiroi H., Orimo A., Hosoi T., Ouchi Y. and Muramatsu M. The complete primary structure of human estrogen receptor β (hER β) and its heterodimerization with ER α *in vivo* and *in vitro*. *Biochem Biophys. Res. Comm.* **243**: 122-126, 1998a.

Ogawa S., Inoue S., Watanabe T., Orimo A., Hosoi T., Ouchi Y. and Muramatsu M. Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of estrogen action in human. *Nucleic Acids Res.* **26**: 3505-3512, 1998b.

Omoto Y., Inoue S., Ogawa S., Toyama T., Yamashita H., Muramatsu M., Kobayashi S. and Iwase H. Clinical value of the wild-type estrogen receptor β expression in breast cancer. *Cancer Lett.* **163**: 207-212, 2001.

Omoto Y., Kobayashi S., Inoue S., Ogawa S., Toyama T., Yamashita H., Muramatsu M., Gustafsson J.A. and Iwase H. Evaluation of oestrogen receptor β wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. *Eur. J. Cancer* **38**: 380-386, 2002.

Ormerod M.G. Analysis of DNA. In: *Flow Cytometry: A Practical Approach*. Ormerod M.G. (ed). 1st edition. IRL Press, New York: pp 69, 1990.

Osborne C.K., Yochmowitz M.G., Knight W.A. and McGuire W.L. The value of estrogen and progesterone receptors in the treatment of breast cancer. *Cancer* **46**: 2884-2888, 1980.

Osborne C.K., Hobbs K. and Trent J.M. Biological differences among MCF-7 human breast cancer cell lines from different laboratories. *Breast Cancer Res. Treat.* **9**: 111-121, 1987.

Osborne C.K., Jarman M., McCague R., Coronado E.B., Hilsenbeck S.G. and Wakeling A.E. The importance of tamoxifen metabolism in tamoxifen-stimulated breast cancer growth. *Cancer Chemother. Pharmacol.* **34**: 89-95, 1994.

Osborne C. Tamoxifen in the treatment of breast cancer. *N. Engl. J. Med.* **339**: 1609-1618, 1998.

Ottoviano Y.L., Issa J.P., Parl F.F., Smith H.S., Baylin S.B. and Davidson N.E. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. *Cancer Res.* **54**: 2552-2555, 1994.

Pace P., Taylor J., Suntharalingam S., Coombes R.C. and Ali S. Human estrogen receptor β binds DNA in a manner similar to and dimerizes with estrogen receptor α . *J. Biol. Chem.* **272**: 25832-25838, 1997.

Paech K., Webb P., Kuiper G.G., Nilsson S., Gustaffson J-A., Kushner P.J. and Scanlan T.S. Differential ligand activation of estrogen receptors ER α and ER β at AP1 sites. *Science (Washington)* **277**: 1508-1510, 1997.

Page M.J., Field J.K., Everett N.P. and Green C.D. Serum regulation of the estrogen responsiveness of the human breast cancer cell line MCF-7. *Cancer Res.* **43**: 1244-1250, 1983.

Paik S., Bryant J., Park C., Fisher B., Tan-Chiu E., Hyams D., Fisher E.R., Lippman M.E., Wickerham D.L. and Wolmark N. *erbB*-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. *J. Natl. Cancer Inst.* **90** (18): 1361-1370, 1998.

Palmieri C., Cheng G.J., Saji S., Zelada-Hedman M., Warri A., Weihua Z., Van Noorden S., Wahlstrom T., Coombes R.C., Warner M. and Gustafsson J.A. Estrogen receptor β in breast cancer. *Endocr. Rel. Cancer* **9**: 1-13, 2002.

Pandey D.P. and Picard D. miR-22 inhibits estrogen signalling by directly targeting the estrogen receptor α mRNA. *Mol. Cell Biol.* **29**: 3783-3790, 2009.

Parazzini F., Colli E., Scatigna M. and Tozzi L. Treatment with tamoxifen and progestins for metastatic breast cancer in postmenopausal women: a quantitative review of published randomized clinical trials. *Oncology* **50**: 483-489, 1993.

Park W., Choi J.J., Hwang E-S. and Lee J-H. Identification of a variant estrogen receptor lacking exon 4 and its coexpression with wild-type estrogen receptor in ovarian carcinomas. *Clin. Cancer Res.* **2**: 2029-2035, 1996.

Parshad R., Sanford K.K., Tarone R.E., Jones G.M and Beack A.E. Increased susceptibility of mouse cells to fluorescent light- induced chromosome damage after long-term culture and malignant transformation. *Cancer Res.* **39**: 929-933, 1979.

Patel P.I., Framson P.E., Caskey C.T. and Chinault A.C. Fine structure of the Human Hypoxanthine Phosphoribosyltransferase Gene. *Mol. Cell Biol.* **6**: 393-403, 1986.

Pedram A., Razandi M., Aitkenhead M., Hughes C.C. and Levin E.R. Integration of the non-genomic and genomic actions of estrogen. Membrane-initiated signalling by steroid to transcription and cell biology. *J. Biol. Chem.* **277**: 50768-50775, 2002.

Pedram A., Razandi M. and Levin E.R. Nature of functional estrogen receptors at the plasma membrane. *Mol. Endocrinol.* **20**: 1996-2009, 2006.

Peng B., Lu B., Leygue E. and Murphy L.C. Putative functional characteristics of human estrogen receptor- β isoforms. *J. Mol. Endocrinol.* **30**: 13-29, 2003.

Perry R.R., Kang Y. and Greaves B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and – independent human breast cancer cells. *Ann. Surg. Oncol.* **2**: 238-245, 1995.

Petersen O.W., Hoyer P.E. and van Deurs B. Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue. *Cancer Res.* **47**: 5748-5751, 1987.

Pfeffer U., Fecarotta E., Castagnetta L. and Vidali G. Estrogen receptor variant messenger RNA lacking exon 4 in estrogen-responsive human breast cancer cell lines. *Cancer Res.* **53**: 741-743, 1993.

Pfeffer U., Fecarotta E. and Vidali G. Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and in MCF-7 cells. *Cancer Res.* **55**: 2158-2165, 1995.

Pfeffer U. Estrogen receptor mRNA variants. Do they have a physiological role? *Ann. N.Y. Acad. Sci.* **784**: 304-313, 1996.

Pichon M.F., Pallud C., Brunet M. and Milgrom E. Relationship of presence of progesterone receptors to prognosis in early breast cancer. *Cancer Res.* **40**: 3357-3360, 1980.

Pike M.C., Krailo M.D., Henderson B.E., Casagrande J.T and Hoel D.G. 'Hormonal' risk factors, 'breast tissue age', and the age incident of breast cancer. *Nature* **303**: 767-70, 1983.

Pink J.J., Jiang S.Y., Fritsch M. and Jordan V.C. An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80- kDa estrogen receptor-related protein. *Cancer Res.* **55**: 2583-2590, 1995.

Pink J.J. and Jordan V.C. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. *Cancer Res.* **56**: 2321-2330, 1996.

Pink J.J., Bilimoria M.M., Assikis J. and Jordan V.C. Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation. *Br. J. Cancer* **74**: 1227-1236, 1996a.

Pink J.J., Wu S.Q., Wolf D.M., Bilimoria M.M. and Jordan V.C. A novel 80 kDa human estrogen receptor containing a duplication of exons 6 and 7. *Nucleic Acids Res.* **24**: 962-969, 1996b.

Pinto A.E., Saudade A. and Soares J. Short term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients. *J. clin. Pathol.* **52**: 604-611, 1999.

Ponglikitmongkol M., Green S. and Chambon P. Genomic organization of the human oestrogen receptor gene. *EMBO J.* **7** (11): 3385-3388, 1988.

Poola I., Koduri S., Chatra S. and Clarke R. Identification of twenty alternatively spliced estrogen receptor α mRNAs in breast cancer cell lines and tumors using slice targeted primer approach. *J. Steroid Biochem. Mol. Biol.* **72**: 249-258, 2000.

Poola I. and Speirs V. Expression of alternatively spliced estrogen receptor alpha mRNAs is increased in breast cancer tissues. *J. Steroid Biochem. Mol. Biol.* **78**: 459-469, 2001.

Poola I., Abraham J. and Baldwin K. Identification of ten exon deleted ER β mRNAs in human ovary, breast, uterus and bone tissues: alternate splicing pattern of estrogen receptor β mRNA is distinct from that of estrogen receptor α . *FEBS Lett.* **516**: 133-138, 2002a.

Poola I., Abraham J. and Liu A. Estrogen receptor β splice variant mRNAs are differentially altered during breast carcinogenesis. *J. Steroid Biochem. Mol. Biol.* **82**: 169-179, 2002b.

Poola I., Clarke R., DeWitty R. and Leffall L.D. Functionally active estrogen receptor isoform profiles in the breast tumors of African American women are different from the profiles in breast tumors of Caucasian women. *Cancer* **94**: 615-623, 2002c.

Press M.F., Bernstein L., Thomas P.A., Meisner L.F., Zhou J.Y., Ma Y., Hung G., Robinson R.A., Harris C., El-Naggar A., Slamon D.J., Phillips R.N., Ross J.S., Wolman S.R. and Flom K.J. HER-2/*neu* gene amplification characterized by

fluorescence in situ: poor prognosis in node-negative breast carcinomas. *J.Clin. Oncol.* **15** (8): 2894-2904, 1997.

Ravdin P.M., Green S., Dorr T.M., McGuire W.L., Fabian C., Pugh R.P., Carter R.T., Rivkin S.E., Borst J.R., Belt R.J., *et al.* Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study. *J. Clin. Oncol.* **10**: 1284-1291, 1992.

Razandi M., Pedram A., Park S.T and Levin E.R. Proximal events in signaling by plasma membrane estrogen receptors. *J. Biol. Chem.* **278**: 2701-2712, 2003a.

Razandi M., Alton G., Pedram A., Ghonshani S., Webb P. and Levin E.R. Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane. *Mol. Cell Biol.* **23**: 1633-1646, 2003b.

Read L.D., Greene G.L. and Katzenellenbogen B.S. Regulation of estrogen receptor messenger ribonucleic acid and protein levels in human breast cancer cell lines by sex steroid hormones, their antagonists, and growth factors. *Mol. Endocrinol.* **3**: 295-304, 1989.

Reddel R.R., Murphy L.C. and Sutherland R.L. Factors affecting the sensitivity of T-47D human breast cancer cells to tamoxifen. *Cancer Res.* **44**: 2398-2405, 1984.

Reddel R.R., Murphy L.C., Hall R.E and Sutherland R.L. Differential sensitivity of human breast cancer cell lines to the growth inhibitory effects of tamoxifen. *Cancer Res.* **45**: 1525-1531, 1985.

Reddel R.E., Alexander I.E., Koga M., Shine J. and Sutherland R.L. Genetic instability and the development of steroid hormone insensitivity in cultured T47D human breast cancer cells. *Cancer Res.* **48**: 4340-4347, 1988.

Reed W., Hannisdal E., Boehler P.J., Gundersen S., Host H. and Marthin J. Prognostic value of p53 and *c-erb* B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma. *Cancer* **88** (4): 804-813, 2000.

Resnicoff M., Medrano E.E., Podhajcer O.L., Bravo A.I., Bover L. and Mordoh J. Subpopulations of MCF7 cells separated by Percoll gradient centrifugation: A model to analyze the heterogeneity of human breast cancer. *Proc. Natl. Acad. Sci. USA* **84**: 7295-7299, 1987.

Rich M.A., Furmanski P. and Brooks S.C. Prognostic value of estrogen receptor determinations in patients with breast cancer. *Cancer Res.* **38**: 4296-4298, 1978.

Ricketts D., Turnbull L., Ryall G., Bakhshi R., Rawson N.S., Gazet J.C., Nolan C. and Coombes R.C. Estrogen and progesterone receptors in the normal female breast. *Cancer Res.* **51**: 1817-1822, 1991.

Rilke F., Colnaghi M.I., Cascinelli N., Andreola S., Baldini M.T., Bufalino R., Della Porta G., Menard S., Pierotti M. A. and Testori A. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. *Int. J. Cancer* **49** (1): 44-49, 1991.

Robertson J.F., Howell A., Gorbunova V.A., Watanabe T., Pienkowski T. and Lichinitser M.R. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. *Br. Cancer Res. Treat.* **92**: 169-174, 2005.

Rody A., Holtrich U., Solbach C., Kourtis K., von Minckwitz G., Engels K., Kissler S., Gatje R., Karn T. and Kaufmann M. Methylation of estrogen receptor β promoter correlates with loss of ER- β expression in mammary carcinoma and is an early indication marker in premalignant lesions. *Endocr. Relat. Cancer* **12**: 903-916, 2005.

Roger P., Sahla M.E., Makela S., Gustafsson J.A., Baldet P. and Rochefort H. Decreased expression of estrogen receptor β protein in proliferative preinvasive mammary tumors. *Cancer Res.* **61**: 2537-2541, 2001.

Roos W., Fabbro D., Kung W., Costa S.D. and Eppenberger U. Correlation between hormone dependency and the regulation of epidermal growth factor receptor by tumour promoters in human mammary carcinoma cells. *Proc. Natl. Acad. Sci. USA* **83**: 991-995, 1986.

Rose C., Thorpe S.M., Anderson K.W., Pedersen B.V., Mouridsen H.T., Blichert-Toft M. and Rasmussen B.B. Beneficial effect of tamoxifen in primary breast cancer patients with high estrogen receptor values. *Lancet* **1**: 16-18, 1985.

Rosen P.P., Lesser M.L., Arroyo G.D., Cranor M., Borgen P. and Norton L. Immunohistochemical detection of HER-2/*neu* in patients with axillary lymph node negative breast carcinoma: a study of epidemiological risk factors, histologic features, and prognosis. *Cancer* **75** (6): 1320-1326, 1995.

Rosenberg L.U., Magnusson C., Lindström E., Wedrén S., Hall P. and Dickman P.W. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. *Breast Cancer Res.* **8**: R11-R24, 2006.

Rowley J.D. Ph-positive leukaemia, including chronic myelogenous leukaemia. *Clin. Haematol.* **9**: 55-86, 1980.

Saez S., Pichon M.F., Cheix F., *et al.* Progesterone receptors and prognosis in early breast cancer. The experience of two centres. In: *Progesterone and progestins*. Baudin C.S., Milgrom E., Mauvais-Jarvis P. (eds). Raven Press, New York: pp 355-366, 1985.

Safe S. Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-SP1 interactions. *Vitam. Horm.* **62**: 231-252, 2001.

Sager R. Genetic instability, suppression, and human cancer. In: L.Sachs (ed.), Gene Regulation in the Expression of Malignancy. London: Oxford University Press, 1985.

Sainsbury J.R., Farndon J.R., Needham G.K., Malcolm A.J. and Harris A.L. Epidermal-growth factor receptor status as predictor of early recurrence of and death from breast cancer. *Lancet* **1**(8547): 1398-1402, 1987.

Saji S., Omoto Y., Shimizu C., Warner M., Hayashi Y., Horiguchi S., Watanabe T., Hayashi S., Gustafsson J.A. and Toi M. Expression of estrogen receptor (ER) (β)cx in ER(α)-positive breast cancer: specific correlation with progesterone receptor. *Cancer Res.* **62**: 4849-4853, 2002a.

Saji S., Omoto Y., Shimizu C., Horiguchi S., Watanabe T., Funata N., Hayashi S., Gustafsson J.A. and Toi M. Clinical impact of assay of estrogen receptor β cx in breast cancer. *Breast Cancer* **9**: 303-307, 2002b.

Sartorius C. A., Melville M.Y., Hovland A.R., Tung L., Takimoto G.S. and Horwitz K.B. A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. *Mol. Endocrinol.* **8**: 1347-1360, 1994a.

Sartorius C.A., Groshong S.D., Miller L.A., Powell L.T., Takimoto G.S. and Horwitz K.B. New T47D breast cancer cell lines for the independent study of progesterone

B- and A-receptors: only antiprogesterin-occupied B-receptors are switched to transcriptional agonists by cAMP. *Cancer Res.* **54**: 3868-3877, 1994b.

Schetter A.J., Leung S.Y., Sohn J.J., Zanetti K.A., Bowman E.D., Yanaihara N., Yuen S.T., Chan T.L., Kwong D.L., Au G.K., Liu C.G., Calin G.A., Croce C.M. and Harris C.C. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. *JAMA* **299**: 425-436, 2008.

Schiff R., Massarweh S., Shou J. and Osborne C.K. Breast cancer endocrine resistance: how growth factor signalling and estrogen receptor coregulators modulate response. *Clinical Cancer Research* **9**: 447S-454S, 2003.

Sedlacek S.M. and Horwitz K.B. The role of progestins and progesterone receptors in the treatment of breast cancer. Review. *Steroids* **44**: 467-484, 1984.

Sempere L.F., Christensen M., Silahatoglu A., Bak M., Heath C.V., Schwartz G., Wells W., Kauppinen S. and Cole C.N. Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer. *Cancer Res.* **67**: 11612-11620, 2007.

Sengupta S. and Jordan V.C. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. *Adv. Exp. Med. Biol.* **630**: 206-219, 2008.

Shackney S.E., Smith C.A., Miller B.W., Burholt D.R., Murtha K., Giles H.R., Ketterer D.M. and Pollice A.A. Model for the genetic evolution of human solid tumors. *Cancer Res.* **49**: 3344-3354, 1989.

Shaw J.A., Udokang K., Mosquera J.M., Chauhan H., Jones J.L. and Walker R.A. Oestrogen receptors α and β differ in the normal human breast and breast carcinomas. *J. Pathol.* **198**: 450-457, 2002.

Shek L.L. and Godolphin W. Survival with breast cancer: The importance of estrogen receptor quantity. *Eur. J. Cancer Clin. Oncol.* **25**: 243-250, 1989.

Sherman M.R., Corval P.L. and O'Malley B.W. Progesterone binding components of chick oviduct. *J. Biol. Chem.* **245**: 6085-6096, 1972.

Singh L., Wilson A.J., Baum M., Whimster W.F., Birch I.H., Jackson I.M., Lowrey C. and Palmer M.K. The relationship between histological grade, oestrogen receptor status, events and survival at 8 years in the NATO ('Nolvadex') trial. *Br. J. Cancer* **57**: 612-614, 1988.

Slater T.F., Sawyer B. and Strauli U. Studies on succinate-tetrazolium reductase systems. III. Points of coupling of four different tetrazolium salts. *Biochim. Biophys. Acta.* **77**: 383, 1963.

Slattery M.L., Potter J.D., Curtin K., Edwards S., Ma K-N., Anderson K., Schaffer D. and Samowitz W.S. Estrogens reduce and withdrawal of estrogens increase

risk of microsatellite instability-positive colon cancer. *Cancer Research* **61**: 126-130, 2001.

Smith C.L. and O'Malley B.W. Coregulator function: A key to understanding tissue specificity of selective receptor modulators. *Endocr. Rev.* **25**: 45-71, 2004.

Soto A.M. and Sonnenschein C. The role of estrogens on the proliferation of human breast tumor cells (MCF-7). *J. Steroid Biochem.* **23**: 87-94, 1985.

Sotoca A.M., van den Berg H., Vervoort J., van der Saag P., Ström A., Gustafsson J-A., Rietjens I. and Murk A.J. Influence of cellular ER α /ER β ratio on the ER α -agonist induced proliferation of human T47D breast cancer cells. *Toxicol. Sci.* **105**: 303-311, 2008.

Soule H.D., Vazquez J., Long A., Abert S. and Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. *J. Natl. Cancer Inst.* **51**: 1409-1413, 1973.

Speirs V., Parkes A.T., Kerin M.J., Walton D.S., Carleton P.J., Fox J.N. and Atkin S.L. Co-expression of estrogen receptor α and β : poor prognostic factors in human breast cancer? *Cancer Res.* **59**: 525-528, 1999.

Spyratos F. DNA content and cell cycle analysis by flow cytometry in clinical samples: application in breast cancer. *Biol. Cell* **78**: 69-72, 1993.

Stål O., Dufmats M., Hatschek T., Carstensen J., Klintenberg C., Rutqvist L.E., Skoog L., Sullivan S., Wingren S. and Nordenskjöld B. S-phase fraction is a prognostic factor in stage I breast carcinoma. *J. Clin. Oncol.* **11**: 1717-1722, 1993.

Stendahl M., Rydén L., Nordenskjöld B., Jönsson P.E., Landberg G and Jirström K. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. *Clin. Cancer Res.* **12**: 4614-4618, 2006.

Ström A., Hartman J., Foster J.S., Kietz S., Wimalasena J. and Gustafsson J.A. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. *Proc. Natl. Acad. Sci. USA* **101**: 1566-1571, 2004.

Suzuki T., Miki Y., Nakamura Y., Moriya T., Ito K., Ohuchi N. and Sasano H. Sex steroid-producing enzymes in human breast cancer. *Endocr. Relat. Cancer* **12**: 701-720, 2005.

Suzuki T., Miki Y., Moriya T., Akahira J., Hirakawa H., Ohuchi N. and Sasano H. In situ production of sex steroids in human breast carcinoma. *Med. Mol. Morphol.* **40**: 121-127, 2007.

Szyczak J., Milewicz A., Thijssen J.H.H., Blankenstein M.A. and Daroszewski J. Concentration of sex steroids in adipose tissue after menopause. *Steroids* **63**: 319-321, 1998.

Takahashi K., Okada M., Ozaki T., Kurioka H., Manabe A., Kanasaki H. and Miyazaki K. Safety and efficacy of oestriol for symptoms of natural or surgically induced menopause. *Hum. Reprod.* **15**: 1028-1036, 2000.

Tartter P.I., Papatestas A.E., Ioannovich J., Mulvihill M.N., Lesnick G. and Aufses A.H. Jr. Cholesterol and obesity as prognostic factors in breast cancer. *Cancer* **47**: 2222-2227, 1981.

Taylor S.E., Martin-Hirsch P.L. and Martin F.L. Oestrogen receptor splice variants in the pathogenesis of disease. *Cancer Lett.* **288**: 133-148, 2010.

Thiebaud D. and Secret R.J. Selective estrogen receptor modulators: mechanism of action and clinical experience. Focus on raloxifene. *Reprod. Fertil. Dev.* **13**: 331-336, 2001.

Thorpe S.M., Rose C., Rasmussen B.B., Mouridsen H.T., Bayer T. and Keiding N. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. *Cancer Res.* **47**: 6126-6133, 1987.

Toi M., Akihko O., Yamada H. and Toge T. Epidermal Growth Factor Receptor expression as a prognostic indicator in breast cancer. *Eur. J. Cancer* **27**: 977-980, 1991.

Toikkanen S., Joensuu H. and Klemi P. The prognostic significance of nuclear DNA content in invasive breast cancer – a study with long- term follow-up. *Br. J. Cancer* **60**: 693-700, 1989.

Tremblay G., Tremblay A., Copeland N., Gilbert D., Jenkins N., Labrie F. and Giguere V. Cloning, chromosomal localization and functional analysis of the murine estrogen receptor β . *Mol. Endocrinol.* **11**: 353-365, 1997.

Twentyman P. and Luscombe M. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. *Br. J. Cancer* **56**: 279-285, 1987.

Umayahara Y., Kawamori R., Watada H., Imano E., Iwama N., Morishima T., Yamasaki Y., Kajimoto Y. and Kamata T. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. *J. Biol. Chem.* **269**: 16433-16442, 1994.

Utsumi T., Harada N., Maruta M. and Takagi Y. Presence of alternatively spliced transcripts of aromatase gene in human breast cancer. *J. Clin. Endocrinol. Metab.* **81**: 2344-2349, 1996.

van Landegham A.A.J., Portman J. and Nabauurs M. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. *Cancer Research* **45**: 2900-2906, 1985

Van Netten J.P., Armstrong J.B., Carlyle S.S., Goodchild N.L., Thornton I.G., Brigden M.L., Coy P. and Fletcher C. Estrogen receptor distribution in the peripheral, intermediate and central regions of breast cancers. *Eur. J. Cancer Clin. Oncol.* **24**: 1885-1889, 1988.

Verghese E.T., Hanby A.M., Speirs V. and Hughes T.A. Small is beautiful: microRNAs and breast cancer – where are we now? *J. Pathol.* **215**: 214-221, 2008.

Vergote I., Robertson J.F.R., Kleeberg U., Burton G., Osborne C.K and Mauriac L. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine treatment. *Br. Cancer Res. Treat.* **79**: 207-211, 2003.

Vladusic E.A., Hornby A.E., Guerra-Vladusic F.K. and Lupu R. Expression of estrogen receptor β messenger RNA variant in breast cancer. *Cancer Research* **58**: 210-214, 1998.

Vogel V.G., Constantino J.P., Wickerham D.L., Cronin W.M., Cecchini R.S., Atkins J.N., Bevers T.B., Fehrenbacher L., Pajon E.R. Jr, Wade J.L. 3rd, Robidoux A., Margolese R.G., James J., Lippman S.M., Runowicz C.D., Ganz P.A., Reis S.E., McCaskill-Stevens W., Ford L.G., Jordan V.C. and Wolmark N. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. *JAMA* **295**: 2727-2741, 2006.

Wada-Hiraike O., Imamov O., Hiraike H., Hultenby K., Schwend T., Omoto Y., Warner M. and Gustafsson J-A. Role of estrogen receptor β in colonic epithelium. *PNAS* **103**: 2959-2964, 2006.

Wakeling A.E., Dukes M. and Bowler J. A potent specific pure antiestrogen with clinical potential. *Cancer Res.* **51**: 3867-3873, 1991.

Wakeling A.E. Similarities and distinctions in the mode of action of different classes of antiestrogens. *Endocr. Relat. Cancer* **7**: 17-28, 2000.

Walker A.R., Adam F.I. and Walker B.F. Breast cancer in black African women: a changing situation. *J. R. Soc. Promot. Health* **2**: 81-85, 2004.

Walter P., Green S., Greene G., Krust A., Bornert J.M., Jeltsch J.M., Staub A., Jensen E., Scrace G., Waterfield M. and Chambon P. Cloning of the human estrogen receptor cDNA. *Proc. Natl. Acad. Sci. USA.* **82**: 7889-7893, 1985.

Wang Y. and Miksicek R.J. Identification of a dominant negative form of the human estrogen receptor. *Mol. Endocrinol.* **5**: 1707-1715, 1991.

Ward H.W.C. Anti-oestrogen therapy for breast cancer: a trial at two dose levels. *Br. Med. J.* **1**: 13-14, 1973.

Warner M.R. Effect of perinatal oestrogen on the pretreatment required for mouse mammary lobular formation *in vitro*. *J. Endocrinol.* **77**: 1-10, 1978.

Watanabe T., Inoue s., Ogawa S., Ishii Y., Hiroi H., Ikeda K., Orimo A. and Muramatsu M. Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors α and β . *Biochem. Biophys. Res. Comm.* **236**: 140-145, 1997.

Webb P., Lopez G.N., Uht R.M. and Kushner P.J. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. *Mol. Endocrinol.* **9**: 443-56, 1995.

Wells A. The epidermal growth factor receptor (EGFR) – a new target in cancer therapy. *Signal* **1**: 4-11, 2000.

Westley B., May F.E.B., Brown A.M.C., Krust A. and Chambon P. Effects of antiestrogens on the estrogen-regulated pS2 RNA 52kDa and 160kDa proteins in MCF-7 cells and two tamoxifen resistant sublines. *J. Biol. Chem.* **259**: 10030-10035, 1984.

Wienand U., Schwarz Z. and Feix G. Electrophoretic elution of nucleic acids from gels adapted for subsequent biological tests: Application for analysis of mRNAs from maize endosperm. *FEBS Lett.* **98**: 319-323, 1979.

Wiseman L.R. and McTavish D. Formestane. A review of its pharmaco-dynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer. *Drugs* **45**: 66-84, 1993.

Wittliff J.L. Steroid-hormone receptors in breast cancer. *Cancer* **53**: 630-643, 1984.

Wolf D.M., Langan-Fahey S.M., Parker S.M., McCague R. and Jordan V.C. Investigation of the mechanism of tamoxifen stimulated breast tumor growth with non-isomerizable analogues of tamoxifen metabolites. *J. Natl. Cancer Inst.* **85**: 806-812, 1993.

Wolf D.M. and Jordan V.C. Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. *Breast Cancer Res. Treat.* **31**: 117-127, 1994.

Woodburn J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. *Pharmacol. Ther.* **82**: 241-250, 1999.

Xing W. and Archer T.K. Upstream stimulatory factors mediate estrogen receptor activation of the cathepsin D promoter. *Mol. Endocrinol.* **12**: 1310-1321, 1998.

Yap O.W.S., Bhat G., Liu L. and Tollefsbol T.O. Epigenetic modifications of the estrogen receptor β gene in epithelial ovarian cancer cells. *Anticancer Res.* **29**: 139-144, 2009.

Yamamoto K.R. Steroid receptor regulated transcription of specific genes and gene networks. *Annu. Rev. Genet.* **19**: 209-252, 1985.

Zauch R., Sosinska-Mielcarek K. and Jassem J. Long-term survival of a patient with primarily chemoresistant metastatic breast cancer treated with medroxyprogesterone acetate. *Breast* **13**: 321-324, 2004.

Zhang Q.X., Hilsenbeck S.G., Fuqua S.A. and Borg A. Multiple splicing variants of the estrogen receptor are present in individual human breast tumours. *J. Steroid Biochem. Mol. Biol.* **59**: 251-260, 1996.

Zhao C., Lam E.W., Sunter A., Enmark E., De Bella M.T., Coombes R.C., Gustafsson J.A. and Dahlman-Wright K. Expression of estrogen receptor β isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. *Oncogene* **22**: 7600-7606, 2003.

Zwijsen R.M., Wientjens E., Klompaker R., van der Sman J., Bernards R. and Michalides R.J. CDK-independent activation of estrogen receptor by cyclin D1. *Cell* **88**: 405-415, 1997.